TDP-43 expression influences amyloidβ plaque deposition and tau aggregation

Neurobiology of Disease

Volumn 103, Issue , 2017, Pages 154-162

  Davis, Stephani A ^a   Gan, Kok Ann ^a   Dowell, James A ^b   Cairns, Nigel J ^c   Gitcho, Michael A ^a  

^a DELAWARE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; APP; APP PS1; Calcineurin; TARDBP; Tau; TDP 43

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CALCINEURIN; PRESENILIN 1; TAR DNA BINDING PROTEIN; TAU PROTEIN; THIOFLAVINE; DNA BINDING PROTEIN; PRESENILIN 1, MOUSE; TDP-43 PROTEIN, HUMAN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APP GENE; ARTICLE; BRAIN CELL; BRAIN CORTEX; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EMBRYO; ENDOSOME; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; HIPPOCAMPUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYSOSOME; MOUSE; NONHUMAN; PROTEIN AGGREGATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PSEN1 GENE; TAUOPATHY; TDP 43 PROTEINOPATHY; TRANSGENIC MOUSE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; GENE EXPRESSION; GENETICS; METABOLISM; PATHOLOGY; PROTEINOSIS;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CELLS, CULTURED; DNA-BINDING PROTEINS; GENE EXPRESSION; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PLAQUE, AMYLOID; PRESENILIN-1; PROTEIN AGGREGATION, PATHOLOGICAL; TAU PROTEINS;

EID: 85018493749     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2017.04.012     Document Type: Article

References (48)

1. Abdul, H.M., et al. Oxidative damage in brain from human mutant APP/PS-1 double knock-in mice as a function of age. Free Radic. Biol. Med. 45 (2008), 1420–1425.
2. Alzheimer's Association, 2017 Alzheimer's disease facts and figures. Alzheimers Dement. 13 (2017), 325–373.
3. Amador-Ortiz, C., et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann. Neurol. 61 (2007), 435–445.
4. Arai, T., et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 351 (2006), 602–611.
5. Arai, T., et al. Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol. 117 (2009), 125–136.
6. Avendano-Vazquez, S.E., et al. Autoregulation of TDP-43 mRNA levels involves interplay between transcription, splicing, and alternative polyA site selection. Genes Dev. 26 (2012), 1679–1684.
7. Ayala, V., et al. Cell stress induces TDP-43 pathological changes associated with ERK1/2 dysfunction: implications in ALS. Acta Neuropathol. 122 (2011), 259–270.
8. Ayala, Y.M., et al. TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J. 30 (2011), 277–288.
9. Borchelt, D.R., et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19 (1997), 939–945.
10. Bose, J.K., et al. Regulation of autophagy by neuropathological protein TDP-43. J. Biol. Chem. 286 (2011), 44441–44448.
11. Buratti, E., et al. Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J. 20 (2001), 1774–1784.
12. Buratti, E., et al. Nuclear factor TDP-43 can affect selected microRNA levels. FEBS J. 277 (2010), 2268–2281.
13. Cataldo, A.M., et al. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. J. Neurosci. 17 (1997), 6142–6151.
14. Cheung, G., Cousin, M.A., Synaptic vesicle generation from activity-dependent bulk endosomes requires calcium and calcineurin. J. Neurosci. 33 (2013), 3370–3379.
15. Clippinger, A.K., et al. Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy. Acta Neuropathol. 126 (2013), 39–50.
16. Colton, C.A., et al. The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP. J. Alzheimers Dis. 15 (2008), 571–587.
17. Davis, S.A. et al., TDP-43 expression influences Aβ plaque deposition, calcineurin expression, and Tau aggregation in the APP/PSEN1 mouse. Alzheimers Dement., 12, 2016, 360.
18. Dolgin, E., How to defeat dementia. Nature 539 (2016), 156–158.
19. Gitcho, M.A., et al. VCP mutations causing frontotemporal lobar degeneration disrupt localization of TDP-43 and induce cell death. J. Biol. Chem. 284 (2009), 12384–12398.
20. Gossen, M., Bujard, H., Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. U. S. A. 89 (1992), 5547–5551.
21. Gu, J., et al. TDP-43 suppresses tau expression via promoting its mRNA instability. Nucleic Acids Res., 2017.
22. Herman, A.M., et al. Beta-amyloid triggers ALS-associated TDP-43 pathology in AD models. Brain Res. 1386 (2011), 191–199.
23. Higashi, S., et al. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. Brain Res. 1184 (2007), 284–294.
24. Hodgkiss, J.P., Kelly, J.S., Only 'de novo' long-term depression (LTD) in the rat hippocampus in vitro is blocked by the same low concentration of FK506 that blocks LTD in the visual cortex. Brain Res. 705 (1995), 241–246.
25. Igaz, L.M., et al. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J. Clin. Invest. 121 (2011), 726–738.
26. Jellinger, K.A., Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia. Neurodegener. Dis. 5 (2008), 118–121.
27. Josephs, K.A., et al. TDP-43 is a key player in the clinical features associated with Alzheimer's disease. Acta Neuropathol., 2014.
28. Kabuta, C., et al. 4-Hydroxynonenal induces persistent insolubilization of TDP-43 and alters its intracellular localization. Biochem. Biophys. Res. Commun. 463 (2015), 82–87.
29. Karch, C.M., et al. Calcium phosphatase calcineurin influences tau metabolism. Neurobiol. Aging 34 (2013), 374–386.
30. LaClair, K.D., et al. Depletion of TDP-43 decreases fibril and plaque beta-amyloid and exacerbates neurodegeneration in an Alzheimer's mouse model. Acta Neuropathol. 132 (2016), 859–873.
31. Li, H.Y., et al. Hyperphosphorylation as a defense mechanism to reduce TDP-43 aggregation. PLoS One, 6, 2011, e23075.
32. Liachko, N.F., et al. The phosphatase calcineurin regulates pathological TDP-43 phosphorylation. Acta Neuropathol., 2016.
33. Lim, Y., et al. Forebrain overexpression of alpha-synuclein leads to early postnatal hippocampal neuron loss and synaptic disruption. Exp. Neurol. 221 (2010), 86–97.
34. Lippa, C.F., et al. Transactive response DNA-binding protein 43 burden in familial Alzheimer disease and Down syndrome. Arch. Neurol. 66 (2009), 1483–1488.
35. Liu-Yesucevitz, L., et al. Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS One, 5, 2010, e13250.
36. Mayford, M., et al. Control of memory formation through regulated expression of a CaMKII transgene. Science 274 (1996), 1678–1683.
37. Mompean, M., et al. An amyloid-like pathological conformation of TDP-43 is stabilized by hypercooperative hydrogen bonds. Front. Mol. Neurosci., 9, 2016, 125.
38. Moujalled, D., et al. Kinase inhibitor screening identifies cyclin-dependent kinases and glycogen synthase kinase 3 as potential modulators of TDP-43 cytosolic accumulation during cell stress. PLoS One, 8, 2013, e67433.
39. Mulkey, R.M., et al. Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depression. Nature 369 (1994), 486–488.
40. Neumann, M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314 (2006), 130–133.
41. Parker, S.J., et al. Endogenous TDP-43 localized to stress granules can subsequently form protein aggregates. Neurochem. Int. 60 (2012), 415–424.
42. Strong, M.J., et al. TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein. Mol. Cell. Neurosci. 35 (2007), 320–327.
43. Uryu, K., et al. Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J. Neuropathol. Exp. Neurol. 67 (2008), 555–564.
44. Walsh, D.M., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002), 535–539.
45. Wang, H.Y., et al. Structural diversity and functional implications of the eukaryotic TDP gene family. Genomics 83 (2004), 130–139.
46. Wilcock, D.M., et al. Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. J. Neurosci. 28 (2008), 1537–1545.
47. Ying, Z., et al. TARDBP/TDP-43 regulates autophagy in both MTORC1-dependent and MTORC1-independent manners. Autophagy 12 (2016), 707–708.
48. Zeng, H., et al. Forebrain-specific calcineurin knockout selectively impairs bidirectional synaptic plasticity and working/episodic-like memory. Cell 107 (2001), 617–629.